"In MPM obtained from p47 knockout mice, where NADPH oxidase is inactive, as well as in control MPMs treated with NADPH oxidase inhibitor, aldosterone did not increase ACE or decrease ACE2."
"Patients with PAH have clinical markers indicating activation of the sympathetic nervous system (i.e., elevated circulating catecholamine levels, muscle sympathetic nerve activity, heart rate variability, decreased MIBG uptake) and the renin-angiotensin-aldosterone system (i.e., increased renin activity, elevated levels of angiotensin I and aldosterone, decreased ACE2 activity and related peptides)."